Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
02/19/2010
Trade Name:
MENVEO
Generic or Proper Name (*):
Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine*
Indications Studied:
Active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135
Therapeutic Category:
Preventive Vaccine
Ages Studied:
11 25 years
Study #:
3
Study Type:
Safety/Immunogenicity
Study Design:
Observer Blind/Controlled
No Patients:
944
No Centers:
14
No Countries:
1
BPCA(B), PREA(P):
P
-
-